Ferhat İÇME, Tuğba TEMREL, Havva Şahin KAVAKLI, Yücel YÜZBAŞIOĞLU, Gülhan Kurtoğlu ÇELİK, Zeynep Saral ÖZTÜRK

Akut Böbrek Yetmezliğinin Nadir Bir Sebebi: Fenofibrata Bağlı Rabdomiyoliz

Fibratlar, dislipidemi ve hipertrigliseridemi tedavisinde sık kullanılan, fibrik asit türevi geniş spektrumlu bir ilaç grubudur. Yan etkileri sıklıkla çizgili kaslar, böbrek ve karaciğer ile ilgilidir. Çizgili kas harabiyetiyle meydana gelen rabdomiyoliz bu yan etkilerin potansiyel olarak en ölümcül olanıdır. Literatürde fenofibrat ve statinlerin kombine kullanılmasına bağlı gelişen rabdomiyoliz vakaları olmasına rağmen tek başına fenofibratın sebep olduğu rabdomiyoliz nadirdir. Bu yazıda akut böbrek hasarlanması tespit ettiğimiz hastada ilaç sorgulamasının öneminin vurgulanması ve fenofibrat kullanımına bağlı gelişen rabdomiyolizin yönetiminin gözden geçirilmesi amaçlanmıştır.

Anahtar Kelimeler:

Fenofibrat; rabdomiyoliz; akut böbrek yetmezliği

A Rare Cause of Acute Renal Failure: Fenofibrate-Induced Rhabdomyolysis

Fibrates are derivative of fibric acid and broad spectrum drugs which are commonly used in the treatment of dyslipidemia and hypertriglyceridemia. Side effects are often related with striated muscles, kidney and liver. Rhabdomyolysis developing with striated muscle destruction is potentially the most lethal of these side effects. Although several case reports of rhabdomyolysis have been reported due to the combination of statin and fenofibrate, fenofibrate alone rarely causes rhabdomyolysis. The purposes of this paper are to present a patient whom we diagnosed with acute renal ınjury due to use of fenofibrate in order to emphasize the importance of questioning drugs which have been used, and to review management of rhabdomyolysis due to fenofibrate use.

Keywords:

Fenofibrate; rhabdomyolysis; acute renal failure,

PDF

___

Melli G, Chaundry V, Cornblath DR. Rhabdomyolysis ; an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005; 84:377-85.
Counselman FL, Lo MB. Rhabdomyolisis. In Tintinalli JE, Kelen GD, Stapczynski JS Emergency Medicine A Comprehensive Study Guide. 7th ed: 622-24. New York: McGraw-Hill. 2010.
Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 1996; 49:314-26.
Odeh M. The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. N Engl J Med. 1991; 324:1417-22.
Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007; 99:3-18.
Clouatre Y, Leblanc M, Ouimet D, Pichette V. Fenofibrate induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephral Dial Transplant. 1999; 14:1047-48.
Ünal A , Sipahioğlu MH, Tokgöz B, Akçakaya M, Coşkun R, Oymak O, ve ark. Antihiperlipidemik Tedavi Sonrası Gelişen Rabdomiyoliz: Üç Olgu Sunumu. Erciyes Tıp Dergisi. 2009;1-4.
Ünal A, Sipahioğlu MH, Tokgöz B, Akçakaya M, Coşkun R, Oymak O, ve ark. Fenofibrate-Induced Acute Renal Failure Due to Massive Rhabdomyolysis after Coadministration of Statin in Two Patients. Inter Med. 2008; 47:1017-19.
Bellomo R, Ronco C, Kellum JA, Meta RL, Palavsky S. Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8: 204.
Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis an evaluation of 475 hospitalized patients. Medicine. 2005; 84:377-85.
Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid lowering drugs. JAMA. 2004; 292:2585-90.
O’Mara SR, Gebreyes K. Hepatic disorders, Joundice and hepatic failure. In Tintinalli JE, Kelen GD, Stapczynski JS Emergency Medicine A Comprehensive Study Guide. 7th ed. New York: McGraw-Hill. 2010; 566-74.
Kellum JA, Cerda J, Kaplan LJ. Fluids for prevention and management of acute kidney injury. Int J Artif Organs. 2008; 31:96-110.
Richards JR. Rhabdomyolysis and drugs of abuse. J Emerg Med. 2000;19: 51-6.
Yazışma Adresi / Address for Correspondence: Dr. Ferhat İçme Ankara Atatürk Eğitim ve Araştırma Hastanesi Acil Servis ANKARA e-mail: ferhaticme@gmail.com geliş tarihi/received :24.09.2012 kabul tarihi/accepted:07.12.2012